Background: Extensively drug-resistant (XDR) tuberculosis (TB) and HIV coinfection is associated with low cure rates and high mortality. Clofazimine has shown activity in vitro against Mycobacterium tuberculosis, but clinical experience with clofazimine in XDR-TB and HIV coinfection is limited.
Introduction
Increasing incidence of extensively drug-resistant (XDR) tuberculosis (TB) 1 has created a need for more effective treatment regimens, 2 especially in XDR-TB/HIV-coinfected patients in whom low cure and high mortality rates prevail. 3, 4 The protracted course of TB drug discovery has stimulated repurposing existing drugs, such as clofazimine. Clofazimine uniquely concentrates within macrophages, ideal for treating slow-growing organisms, 5, 6 with demonstrated improved culture conversion in murine models and success in shortening treatment duration in a multidrug-resistant (MDR) TB case series. 7, 8 Clofazimine has been incorporated into treatment guidelines for severe drug-resistant TB. 9 An XDR-TB systematic review demonstrated a treatment success rate of 66% with clofaziminecontaining regimens. 10 However, published studies provide few data supporting its use in XDR-TB/HIV coinfection. 10 -12 We performed a retrospective cohort study to evaluate the effect of clofazimine-containing regimens on culture conversion in XDR-TB/HIV coinfection.
Methods
We reviewed the case records of patients ≥18 years with microbiologically confirmed XDR-TB, admitted to a specialist TB hospital in KwaZulu-Natal, South Africa, between August 2009 and July 2011. Patients were excluded if they had a history of XDR-TB treatment, clofazimine added to their regimen subsequent to treatment initiation or unavailable TB culture results. Antimycobacterial treatment regimens, including clofazimine, were determined by treating physicians based on clinical judgement, susceptibility results and safety parameters.
Eligible patients were stratified into two treatment groups: those treated with a clofazimine-containing regimen (clofazimine group) and those treated without clofazimine (non-clofazimine group). Treatment regimens were tailored to the isolate's susceptibility. The clofazimine dosage used was either 200 or 300 mg daily based on weight, 13 with regimen change due to clofazimine-related adverse events noted.
Data collection
A standardized data extraction form was used. The variables collected are presented in Tables 1 and 2 and were obtained as part of standard clinical care.
Culture and drug susceptibility testing (DST)
Mycobacterium tuberculosis was cultured using BACTEC MGIT 960 (Becton Dickinson, Sparks, MD, USA) and 7H11 Middlebrook medium with DST by the 1% proportion method. 14 
Outcome, definitions and follow-up
Standard treatment outcome definitions as per Laserson et al. 15 were used. The primary outcome was time to culture conversion, which was defined as the time from treatment initiation to the date of the first of two consecutive negative cultures ≥1 month apart. Sputum outcomes were measured up to 12 months.
Statistical analysis
Comparisons between patients in both groups were performed using either Fisher's exact test (categorical data) or the Wilcoxon rank sums test (continuous data). Patients who did not culture convert were censored at their last follow-up visit (recorded by sputum collection dates). For the 6 month culture conversion analysis, time to conversion was censored at 6 months. Proportional hazards regression analyses were performed to assess factors associated with 6 month culture conversion.
Ethics approval
The study was approved by the Albert Einstein College of Medicine and the University of KwaZulu-Natal.
Results
During August 2009 to July 2011, 204 patients were admitted for XDR-TB treatment with culture-confirmed XDR-TB at baseline. Eighty-five patients met the inclusion criteria; 50 newly diagnosed with XDR-TB were treated with clofazimine ('clofazimine group') and 35 patients were treated with a non-clofazimine-containing regimen ('non-clofazimine group'). The remaining 119 patients were excluded: pre-XDR-TB (n¼ 18); history of XDR-TB treatment (n ¼ 30) (excluded due to pre-exposure to study drugs); no M. tuberculosis culture (n ¼ 16); and clofazimine added to XDR-TB treatment (n¼ 55).
Both groups were similar for baseline characteristics (Table 1) .
Patients were followed for a maximum of 12 months after XDR-TB treatment initiation (median follow-up 7.7 months, IQR 5.3-11.8). Thirty of 85 patients (35.3%) culture converted. Median time to culture conversion was 13.5 weeks (IQR 8.9-20.4). In the clofazimine group, 20/50 (40%) patients culture converted and in the non-clofazimine group, 10/35 (28.6%) culture converted (P ¼ 0.05). Median time to culture conversion was 16.4 weeks (IQR 9.0 -24.7) in the clofazimine group and 11.9 weeks (IQR Padayatchi et al. 8.6 -18.4) in the non-clofazimine group (P ¼ 0.37). In the first 2 months of treatment, there was no difference in the probability of culture conversion between groups. After 2 months, the probability of culture conversion was higher in the clofazimine group (Figure 1) . By month 4, 32% of patients in the clofazimine group and 16% in the non-clofazimine group culture converted. In both groups, most culture conversions occurred within the first 6 months. In the clofazimine group, 18/20 culture conversions occurred before 6 months, while the remaining 2 converted before 12 months. Similarly, in the non-clofazimine group, 8/10 culture conversions occurred before 6 months and the remaining 2 before 12 months. Patients in the clofazimine group were twice as likely to culture convert within 6 months after XDR-TB treatment initiation. Year of starting XDR-TB treatment also had an impact on culture conversion. HIV status, antiretroviral (ARV), sex and age did not affect 6 month culture conversion ( Table 2) . Baseline chest radiograph (CXR) score was not associated with Clofazimine in the treatment of HIV-associated XDR-TB 3105 JAC 6 month culture conversion; however, change in CXR score by 6 months was statistically significant (Table 2) . 16 Among XDR-TB/HIV-coinfected patients, none of the baseline characteristics (Table 1) was associated with TB culture conversion at 6 months. Clofazimine showed a similar magnitude of effect as in the overall group, but this was not statistically significant. However, in the adjusted analysis, year of treatment initiation was significantly associated with culture conversion (Table 2 ). During 2009-11, the median number of TB medications patients received increased (P ¼ 0.02) as well as the proportion initiating ARVs (trend P ¼ 0.04).
Data regarding adverse reactions were available in 42/50 patients in the clofazimine group. Most patients (32/42) did not experience a clofazimine-related adverse reaction: 6 patients (14%) had a skin reaction; 3 (7%) had mild nausea and diarrhoea; and 1 became confused (2%). Clofazimine was discontinued in 3/10 patients due to severe vomiting (n ¼ 1), confusion (n ¼ 1) and skin discoloration (n¼ 1). Most patients with adverse events were HIV infected.
Overall, 43.5% (37/85) died or were lost to follow-up and only 12.9% (11/85) were cured or completed treatment. There was no significant difference between the proportion of deaths in the clofazimine group versus the non-clofazimine group [36.0% (18/50) versus 54.3% (19/35), P ¼ 0.1212]. In the clofazimine group, 58.0% (29/50) were lost to follow-up and at the last visit, 50% (14/28) were still culture positive (median time of 7 months, range 3-15 months).
Discussion
We demonstrated that XDR-TB patients, the majority coinfected with HIV, are more than twice as likely to culture convert (hazard rate ratio 2.54, 95% CI 0.99-6.52, P¼0.05) when treated with a clofazimine-containing regimen compared with patients treated with non-clofazimine-containing regimens in the same setting. Whilst few studies describe the effect of clofazimine in XDR-TB, even fewer report XDR-TB with HIV coinfection. In a long-term study of XDR-TB treatment elsewhere in South Africa, with lower HIV prevalence, clofazimine was an independent predictor of culture conversion. 4 Similar benefits were seen in HIV-uninfected patients in Shanghai and Bangladesh, with low treatment failure. 7, 17 The culture conversion rate in the clofazimine group was 40% compared with 28.6% in the non-clofazimine group (P ¼ 0.05). Although higher than the 20% culture conversion rates previously described, 18 it was lower than the 56.4% achieved in non-HIV settings. 17 In Bangladesh, the treatment of MDR-TB showed clofazimine-containing regimens were the most effective, with cure rates as high as 84.2% in an HIV-uninfected cohort. 7 Time to culture conversion was shorter in the non-clofazimine group compared with the clofazimine group, although not statistically significant. In the first 2 months, there was no difference in culture conversion between the groups. After 2 months, the probability of culture conversion was higher in the clofazimine group. In both groups, most of the culture conversions occurred within the first 6 months. The delayed contribution of clofazimine may result from extensive binding and time required to accumulate in tissues, to reach binding saturation and then permit release of microbiologically active free drug. In addition, its ability to concentrate in macrophages and long half-life may result in sustained efficacy synergistic with pyrazinamide. 19 Consistent with data from uncontrolled studies, HIV status, ARV and CD4 count did not affect M. tuberculosis culture conversion at 6 months. 3 Although there has been some suggestion of worse outcome with clofazimine in HIV-coinfected patients with XDR-TB, 4 this was not seen in our study. Our study demonstrates that clofazimine as part of a background treatment regimen improves M. tuberculosis culture conversion and has the potential to improve treatment outcomes in XDR-TB/HIV-coinfected patients. Early initiation of ART in MDR-TB patients has been shown to reduce mortality by 86%. 20 Integrated XDR-TB and HIV treatment will likely improve outcomes in dually infected patients. The limited data on radiological improvement may serve as a surrogate marker of culture conversion.
The optimal dose of clofazimine has not been defined. In this study, patients received either 200 or 300 mg of clofazimine daily, 13 higher than in other studies. 7, 17 Few adverse events were reported even in HIV-infected patients, most of whom were also receiving an ARV, but these were minor with low treatment stoppages, similar to published reports.
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Our study has several limitations. The decision to initiate clofazimine treatment was made by the individual treating physician with no uniform criteria, thus selection bias may exist. Clofazimine susceptibility testing was unavailable. The review was limited to 12 months and the improved rates of culture conversion may not translate to improved cure at 24 months. Significant attrition in this cohort restricts inferences of final outcome.
The small sample and the retrospective analysis limit our study conclusion. Clofazimine was used as part of an individualized treatment regimen including on average six other medications, so outcomes cannot be definitively ascribed to clofazimine. Despite these limitations, our study adds important knowledge on the subject of clofazimine for the treatment of XDR-TB in a largely HIV-infected cohort, demonstrating improved culture conversion with minor adverse events.
In the absence of new drugs and effective treatment options, repurposing clofazimine as an additional drug for XDR-TB treatment increases therapeutic options, even in high HIV prevalence settings. Due to the paucity of clinical efficacy of clofaziminecontaining regimens, the authors suggest the need for a controlled clinical trial.
